Stifel lowered the firm’s price target on MaxCyte (MXCT) to $9 from $11 and keeps a Buy rating on the shares. Management’s guidance for 2025 ...

MaxCyte Raises Q4 Guidance Driven by SPL Revenue MaxCyte sells electroporation tools and Strategic Platform License (SPLs). The net present value (NPV) of an SPL is $85 million, according to MaxCyte.

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy ...

The deal came together about a year after a big leadership change. MaxCyte Inc. has made its first acquisition in its more than quarter-century of operation, about a year after its current CEO ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever MaxCyte, Inc, a life sciences company, discovers, develops, and ...

ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform ...

MaxCyte, Inc. announced a strategic platform license agreement with TG Therapeutics, a biopharmaceutical company specializing in treatments for B-cell diseases. Under this agreement, TG ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use ...